Medizone International (MZEIQ) 10-K 20 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 20, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Medizone International Inc
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		415,191,788
Entity Public Float			$ 30,499,200
Amendment Flag	false
Entity Central Index Key	753,772
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 29,623	$ 398,290
Inventory	290,057	109,573
Prepaid expenses	23,303	81,666
Total current assets	342,983	589,529
Other assets:
Trademark and patents, net	117,616	151,444
Lease deposit	2,823	4,272
Total other assets	120,439	155,716
Total assets	463,422	745,245
Current liabilities:
Accounts payable	637,557	459,654
Accounts payable – related parties	40,415	0
Accrued expenses	630,899	592,621
Accrued expenses – related parties	780,044	538,887
Other payables	224,852	224,852
Notes payable	362,223	297,332
Notes payable – related parties	1,643,578	1,617,881
Warrant liability	690,508	985,163
Total current liabilities	5,010,076	4,716,390
Notes payable, net of current portion	0	75,000
Total liabilities	5,010,076	4,791,390
Commitments and contingencies (Notes 5,6,10 and 12)
Stockholders’ deficit:
Preferred stock, $0.00001 par value: 50,000,000 authorized; no shares outstanding	0	0
Common stock, $0.001 par value: 500,000,000 authorized; 408,317,402 and 393,934,068 shares issued and outstanding, respectively	408,317	393,934
Additional paid-in capital	35,185,874	33,680,146
Accumulated other comprehensive loss	(54,864)	(48,043)
Accumulated deficit	(40,085,981)	(38,072,182)
Total stockholders’ deficit	(4,546,654)	(4,046,145)
Total liabilities and stockholders’ deficit	$ 463,422	$ 745,245

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	408,317,402	393,934,068
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares outstanding	408,317,402	393,934,068

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues	$ 0	$ 237,000
Operating expenses:
Cost of revenues	0	203,460
General and administrative	1,909,046	2,068,391
Research and development	257,312	501,734
Depreciation and amortization	52,442	56,311
Total operating expenses	2,218,800	2,829,896
Loss from operations	(2,218,800)	(2,592,896)
Gain (loss) on warrant liability	294,655	(47,212)
Interest expense	(89,685)	(33,850)
Interest income	31	122
Net loss	(2,013,799)	(2,673,836)
Other comprehensive loss:
Loss on foreign currency translation	(6,821)	(11,075)
Total comprehensive loss	$ (2,020,620)	$ (2,684,911)
Basic and diluted net loss per common share (in Dollars per share)	$ (0.01)	$ (0.01)
Weighted average number of common shares outstanding (in Shares)	400,207,813	375,118,494

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015	$ 369,434	$ 32,496,646	$ (36,968)	$ (35,398,346)	$ (2,569,234)
Balance (in Shares) at Dec. 31, 2015	369,434,068
Common stock issued for services	$ 500	47,500			48,000
Common stock issued for services (in Shares)	500,000
Common stock issued for cash	$ 24,000	1,136,000			1,160,000
Common stock issued for cash (in Shares)	24,000,000
Loss on foreign currency translation			(11,075)		(11,075)
Net loss				(2,673,836)	(2,673,836)
Balance at Dec. 31, 2016	$ 393,934	33,680,146	(48,043)	(38,072,182)	$ (4,046,145)
Balance (in Shares) at Dec. 31, 2016	393,934,068				393,934,068
Common stock issued for services	$ 250	17,250			$ 17,500
Common stock issued for services (in Shares)	250,000
Common stock issued for cash	$ 11,833	663,167			$ 675,000
Common stock issued for cash (in Shares)	11,833,334				11,833,334
Restricted stock awards	$ 2,300	225,700			$ 228,000
Restricted stock awards (in Shares)	2,300,000				2,300,000
Warrant to purchase common stock issued for services		33,960			$ 33,960
Stock-based compensation		565,651			565,651
Loss on foreign currency translation			(6,821)		(6,821)
Net loss				(2,013,799)	(2,013,799)
Balance at Dec. 31, 2017	$ 408,317	$ 35,185,874	$ (54,864)	$ (40,085,981)	$ (4,546,654)
Balance (in Shares) at Dec. 31, 2017	408,317,402				408,317,402

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Common stock for cash, per share	$ 0.06
Minimum [Member]
Common stock issued for services, per share	0.06
Maximum [Member]
Common stock issued for services, per share	0.15
Common Stock [Member]
Common stock issued for services, per share	0.07	$ 0.096
Common Stock [Member] | Minimum [Member]
Common stock for cash, per share	0.05	0.04
Common Stock [Member] | Maximum [Member]
Common stock for cash, per share	$ 0.06	$ 0.05

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (2,013,799)	$ (2,673,836)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	565,651	0
Stock issued for compensation	228,000	0
Depreciation and amortization	52,442	56,311
Fair value of warrants issued for services	33,960	937,951
Stock issued for services	17,500	48,000
Change in warrant liability	(294,655)	47,212
Changes in operating assets and liabilities:
Inventory	(180,484)	168,250
Prepaid expenses	96,503	17,075
Lease deposits	1,449	0
Accounts payable and accounts payable – related parties	218,318	(36,389)
Accrued expenses and accrued expenses – related parties	279,435	37,787
Net cash used in operating activities	(995,680)	(1,397,639)
Cash flows from investing activities:
Expenditures for trademark and patents	(18,613)	(31,255)
Net cash used in investing activities	(18,613)	(31,255)
Cash flows from financing activities:
Principal payments on notes payable	(22,553)	(66,819)
Issuance of common stock for cash	675,000	1,160,000
Net cash provided by financing activities	652,447	1,093,181
Effects of foreign currency exchanges rates on cash	(6,821)	(11,075)
Net decrease in cash	(368,667)	(346,788)
Cash as of beginning of the year	398,290	745,078
Cash as of end of the year	29,623	398,290
Supplemental disclosure of cash flow information:
Cash paid for interest	5,728	12,956
Supplemental disclosure of non-cash financing activities:
Financing of insurance premiums	38,141	66,755
Settlement of accounts payable and accrued expenses with notes payable – related party	$ 0	$ 1,617,881

NOTE 1 - ORGANIZATION AND SUMMA

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Organization The consolidated financial statements presented are those of Medizone International, Inc. (“Medizone”), Medizone Canada, Inc., a wholly owned subsidiary, and the Canadian Foundation for Global Health (“CFGH”) (“Affiliate”), a not-for-profit foundation based in Ottawa, Canada, considered to be a variable interest entity (“VIE”) as described below. Collectively, they are referred to herein as the “Company.” In late 2008, the Company assisted in the formation of CFGH, a not-for-profit foundation. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of its technology to as many in need as possible. US generally accepted accounting principles (“US GAAP”) require a VIE to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests (ownership, contractual, or other financial interests) in the VIE. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the financial results of the VIE with it. Accordingly, the financial position and results of operations of CFGH are consolidated with Medizone as of and for the years ended December 31, 2017 and 2016. The noncontrolling interest portion of net assets and net loss not attributable, directly or indirectly, to Medizone International, Inc. is considered immaterial. b. The Company is a global provider of disinfection systems. The Company invented the AsepticSure ® ® c. Basic and Diluted Net Loss Per Common Share The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the years as follows: For the Years Ended 2017 2016 Numerator (net loss) $ (2,013,799 ) $ (2,673,836 ) Denominator (weighted average number of common shares outstanding – basic and diluted) 400,207,813 375,118,494 Basic and diluted net loss per common share $ (0.01 ) $ (0.01 ) As of December 31, 2017, common stock equivalents, consisting of 18,087,500 options, warrants to purchase 1,750,000 shares of common stock, and warrants to purchase up to $1,000,000 of common stock with the number of shares determined based on a 20-day average stock price prior to the date of exercise, have not been included in the calculation, as their effect is antidilutive for the year ended December 31, 2017. As of December 31, 2016, common stock equivalents, consisting of 20,715,000 options and warrants to purchase up to $1,000,000 of common stock with the number of shares to be determined based on similar terms as in 2017, have not been included in the calculation, as the effect is antidilutive for the year ended December 31, 2016. d. Property and equipment are recorded at cost. Any major additions and improvements are capitalized. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as gain or loss on sale of property and equipment. Depreciation is computed using the straight-line method over periods of three years for computers and software, and five years for office equipment and furniture. e. Provision for Income Taxes The Company estimates income taxes in each of the jurisdictions in which it operates. This process involves estimating the Company’s actual current income tax expense together with assessing temporary differences resulting from differing treatment of items for income tax and financial reporting purposes. These temporary differences result in deferred income tax assets and liabilities, the net amount of which is included in the Company’s consolidated balance sheets. When appropriate, the Company records a valuation allowance to reduce its deferred income tax assets to the amount that the Company believes is more likely than not to be realized. Key assumptions used in estimating a valuation allowance include potential future taxable income, projected income tax rates, expiration dates of net operating loss (“NOL”) and tax credit carry forwards, and ongoing prudent and feasible tax planning strategies. As of December 31, 2017, the Company had NOL carryforwards of approximately $14,087,000 that may be offset against future taxable income, if any, and expire through 2035. If substantial changes in the Company’s ownership should occur, there would also be an annual limitation of the amount of the NOL carryforwards available for use. No tax benefit has been reported in the consolidated financial statements as, in the opinion of management, it is more likely than not that all of the deferred income tax assets will not be realized and the NOL carryforwards will expire unused. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. If the Company were to determine that it would be able to realize its deferred income tax assets in the future in excess of the net recorded amount, an adjustment to reduce the valuation allowance would increase net income or decrease net loss in the period such determination was made. Interest and penalties associated with any underpayment of income taxes would be classified as income tax provision in the statements of comprehensive loss. The Company has elected to present revenues net of any tax collected. Deferred income tax assets as of December 31, 2017 and 2016 comprised the following: 2017 2016 Net operating loss carryforwards $ 3,514,700 $ 4,959,900 Related party accruals 980,100 1,564,700 Valuation allowance (4,494,800 ) (6,524,600 ) $ - $ - The income tax benefit differs from the amount determined by applying the U.S. federal income tax rate to pretax loss for the years ended December 31, 2017 and 2016 due to the following: 2017 2016 Income tax benefit based on U.S. statutory rate of 34% $ (684,700 ) $ (909,100 ) Effect of change in deferred tax rates (39.834% to 24.95%) 2,681,404 - Other 33,096 (40,800 ) Change in valuation allowance (2,029,800 ) 949,900 $ - $ - The Company had no uncertain income tax positions as of December 31, 2017, and 2016. The Company files income tax returns in the U.S. federal, California and Michigan jurisdictions. With few exceptions, the Company is no longer subject to US federal, state and local tax examinations for years before 2014. On December 22, 2017, the Tax Cuts and Jobs Act (the Tax Act) was enacted. The Tax Act makes broad and complex changes to the US tax code that will affect our fiscal year ending December 31 2018, including, but not limited to (1) reducing the US federal corporate tax rate from 35 percent to 21 percent; (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (3) requiring a current inclusion in US federal taxable income of certain earnings of controlled foreign corporations; (4) creating a new limitation on deductible interest expense; (5) revising the rules that limit the deductibility of compensation to certain highly compensated executives, and (6) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. The SEC staff issued SAB 118, which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. As a result of changes made by the Tax Act, Section 162(m) will limit the deduction of compensation, including performance-based compensation, in excess of $1 million paid to anyone who, for tax years beginning after January 1, 2018, serves as the Chief Executive Officer or Chief Financial Officer, or who is among the three most highly compensated executive officers for any fiscal year. The only exception to this rule is for compensation that is paid pursuant to a binding written contract in effect on November 2, 2017 that would have otherwise been deductible under the prior Section 162(m) rules. Accordingly, any compensation paid in the future pursuant to new compensation arrangements entered into after November 2, 2017, even if performance-based, will count towards the $1 million fiscal year deduction limit if paid to a covered executive. The Company estimates that there will not be a material impact during the current quarter or fiscal year, as the law is effective for tax years beginning after January 1, 2018. The Company has evaluated its binding contracts entered into prior to November 2, 2017 and believes there will be no material impact on the Company’s balance sheet. The Company is still analyzing certain aspects of the Act and refining calculations, which could potentially affect the impact of the Company’s deferred tax asset and this provision. f. Principles of Consolidation The consolidated financial statements include the accounts of Medizone and the accounts of Medizone Canada, Inc., a wholly-owned subsidiary incorporated in Canada, and CFGH, a VIE. All material intercompany accounts and transactions have been eliminated. g. Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of the contingent assets and liabilities as of the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. h. Advertising The Company expenses the costs of advertising as incurred. The Company did not incur any advertising expense for the years ended December 31, 2017 and 2016. i. The Company records compensation expense in connection with the granting of stock options and their vesting periods based on their fair values. The Company estimates the fair values of stock option awards issued to employees, consultants and others by using the Black-Scholes option-pricing model. For stock options with a service condition, the expense is measured at the grant date and expensed over the vesting period. For stock options with a performance condition, the expense is measured when it is probable that the performance condition will be met, subsequently re-measured at each reporting date, and trued up upon the final completion of the performance condition. j. The Company accounts for certain common stock warrants as liabilities. The fair value of the common stock warrant liability is determined at each reporting period-end, with the changes in fair value recognized as gain (loss) on change in fair value of warrant liability. The fair value of the warrants to purchase common stock is estimated using the Black-Scholes valuation model. The significant assumptions used in estimating the fair value of warrant liabilities include the exercise price, volatility of the stock underlying the warrant, risk-free interest rate, estimated fair value of the stock underlying the warrant and the estimated life of the warrant. k. Trademark and patents are recorded at cost. Amortization is computed using the straight-line method over a period of seven years. The Company evaluates the recoverability of intangibles and reviews the amortization period on a continual basis. Several factors are used to evaluate intangibles, including management’s plans for future operations, recent operating results, and projected, undiscounted net cash flows. l. The Company recognizes revenue when it ships its products, title and risk of loss passes to customers, payment from the customer is reasonably assured and the price is fixed or determinable. The Company records customer deposits received in advance of shipping products as a liability. m. The Company’s inventory consists of its AsepticSure ® n. The Company’s financial instruments consist of cash, accounts payable, accrued expenses, notes payable and warrant liability. The carrying amounts of cash, accounts payable, and accrued expenses approximate their fair values because of the short-term nature of these instruments. The carrying amounts of the notes payable approximate fair values as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments. The fair value of the warrant liability represents its estimated fair value using the Black-Scholes option pricing model. The Company measures certain financial liabilities (warrant liability) at fair value on a recurring basis. The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: · Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. · Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly. · Level 3 measurements are unobservable inputs. o. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) In February 2016, the FASB released ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting In October 2016, the FASB issued ASU No. 2016-17, Interests held Through Related Parties That are Under Common Control In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718) p. Concentration of Credit Risk The Company maintains its cash in bank deposit accounts which cash, at times, exceeds federally insured limits. As of December 31, 2017, the Company did not have cash balances that exceeded US federally insured limits. To date, the Company has not experienced a material loss or lack of access to its cash; however, no assurance can be provided that access to the Company’s cash will not be impacted by adverse conditions in the financial markets.

NOTE 2 INVENTORY

NOTE 2 INVENTORY	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	NOTE 2 – INVENTORY In December 2016, the Company terminated a Distribution and License Agreement with a distributor due to a lack of market development by the distributor. In connection with the termination, the Company negotiated the return of five disinfection units on or before January 17, 2017 paying the distributor $25,000 per unit. The units were upgraded with the Company’s current technology to support the ongoing expansion of the Company’s commercial strategy.

NOTE 3 - TRADEMARK AND PATENTS

NOTE 3 - TRADEMARK AND PATENTS	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 3 - TRADEMARK AND PATENTS Trademark and patents consist of the following as of December 31, 2017 and 2016: 2017 2016 Patent costs $ 433,865 $ 415,251 Trademark 770 770 434,635 416,021 Accumulated amortization (317,019 ) (264,577 ) Trademark and patents, net $ 117,616 $ 151,444 Amortization expense for the years ended December 31, 2017 and 2016, was $52,442 and $55,896, respectively. The future amortization as of December 31, 2017, is as follows: 2018-$41,409; 2019-$27,745; 2020-$20,203; 2021-$12,956; 2022-$8,412 and thereafter-$6,891.

NOTE 4 - ACCOUNTS PAYABLE - REL

NOTE 4 - ACCOUNTS PAYABLE - RELATED PARTIES	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	NOTE 4 - ACCOUNTS PAYABLE – RELATED PARTIES As of December 31, 2017, and 2016, the Company owed $40,415 and $0 to directors and officers for various administrative and travel related expenses. In July 2016, the Company converted $228,109 of accounts payable – related parties into notes payable – related parties (see Note 8).

NOTE 5 - ACCRUED EXPENSES

NOTE 5 - ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	NOTE 5 - ACCRUED EXPENSES Accrued expenses consist of the following as of December 31, 2017 and 2016: 2017 2016 Accrued interest $ 577,978 $ 549,909 Other accruals 52,921 42,712 Total $ 630,899 $ 592,621 Accrued interest pertains to notes payable (see Note 7). Other accruals consist of legal and advisory fees, estimated taxes and product warranties.

NOTE 6 - ACCRUED EXPENSES - REL

NOTE 6 - ACCRUED EXPENSES - RELATED PARTIES	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 - ACCRUED EXPENSES – RELATED PARTIES Accrued expenses – related parties consist of the following as of December 31, 2017 and 2016: 2017 2016 Accrued payroll and consulting – related parties $ 648,167 $ 422,334 Accrued payroll taxes – related parties 131,877 116,553 Total $ 780,044 $ 538,887 In July 2016, the Company converted $1,389,772 of accrued expenses – related parties into notes payable – related parties. These parties are officers and executives of the Company (see Note 8). Accrued payroll and consulting fees increased during 2017, as the Company’s Interim CEO, current CEO, and Executive Vice President, Administration and Operations have deferred their salaries until such time as a significant financing has occurred.

NOTE 7 - NOTES PAYABLE

NOTE 7 - NOTES PAYABLE	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 7 - NOTES PAYABLE Notes payable consist of the following as of December 31, 2017 and 2016: 2017 2016 Unsecured notes payable to former directors and a family member of a former director, due at various dates in 1995, 1996 and 1997, interest at 8%. The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. These notes payable are in default. $ 182,676 $ 182,676 Unsecured notes payable to a third party in the amount of $50,000, due on September 8, 2018, interest at 12%. Accrued interest due semi-annually, January 5 and July 5 of each year. The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share. 50,000 50,000 Unsecured notes payable to 10 stockholders, due on demand, interest at 10%. The Company is obligated to accept the principal at face value plus accrued interest as partial payment for shares the lenders may purchase from the Company upon exercise of the lenders’ option to acquire shares from the Company. 60,815 60,815 Unsecured notes payable to a third party in the amount of $25,000, due on September 17, 2018, interest at 12%. Accrued interest due semi-annually, January 5 and July 5 of each year. The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share. 25,000 25,000 Unsecured notes payable to directors totaling $28,000 and a note payable to a third party in the amount of $9,000, due on April 22, 1995, interest at 8%. Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. These notes payable are in default. 37,000 37,000 Unsecured notes payable to a financing company, payable in nine monthly installments, interest ranging from 5.1% to 7.3%, maturing in April, July and October 2018. 6,732 16,841 Total notes payable 362,223 372,332 Less notes payable current portion (362,223 ) (297,332 ) Total notes payable long term, net of current portion $ - $ 75,000

NOTE 8 - NOTES PAYABLE - RELATE

NOTE 8 - NOTES PAYABLE - RELATED PARTIES	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 8 - NOTES PAYABLE – RELATED PARTIES In July 2016, the Company converted $228,109 of accounts payable – related parties, and $1,389,772 of accrued expenses – related parties into three promissory notes aggregating $1,617,881. The amounts converted represent accrued expenses and accrued wages prior to 2009 owed to certain officers and executives of the Company. The three notes have similar terms and specify payment terms, trigger events and a default rate of 5% per annum. During 2017, the Company made total payments towards the principal of $23,202 The Company is currently in default with the terms of the promissory notes and is accruing interest at 5% per annum on the outstanding balance, with any payments made to be applied towards interest first. As of December 31, 2017, the Company owes $48,899 in accrued interest related to these notes (see Note 10).

NOTE 9 - WARRANT LIABILITY

NOTE 9 - WARRANT LIABILITY	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 9 - WARRANT LIABILITY The Company accounts for its common stock warrants under ASC 480, Distinguishing Liabilities from Equity. In October 2016, the Company issued warrants to purchase up to $1,000,000 in common stock with the number of shares to be determined based on a 20-day average stock price prior to the date of exercise, discounted 40%. The warrants were exercisable between January 31, 2017 and January 30, 2018. Since the price of the warrants was yet to be determined, the Company recorded a common stock warrant liability of $937,951 on the warrants’ issuance date and, revalued the warrants on December 31, 2017 and 2016. The estimate was calculated using the following inputs: Input December 31, 2017 December 31, 2016 Risk-free interest rate 1.28 % .85 % Expected life in years 1 month 1 year Dividend yield — — Volatility 136.3 % 120.0 % Stock price $ 0.04 $ 0.11 For the year ended December 31, 2017, the Company recorded a decrease of $294,655 in the warrant liability, for a total liability of $690,508. The warrants expired on January 30, 2018.

NOTE 10 - COMMITMENTS AND CONTI

NOTE 10 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 10 - COMMITMENTS AND CONTINGENCIES Litigation The Company may be subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. Rakas vs. Medizone International, Inc. Related Party Agreements In July 2016, the Company issued notes to its former CEO Edwin Marshall, former Director of Operations, Jill Marshall, and Michael Shannon, President of CFGH that were in settlement of $228,109 of accounts payable – related parties, and $1,389,772 of accrued expenses – related parties into three promissory notes payable – related parties aggregating to $1,617,881. The principal amounts of the promissory notes issued were $1,065,189; $444,583 and $111,109, respectively. The promissory notes were issued in settlement of our liability to these three individuals for accrued and unpaid compensation owed for periods prior to December 31, 2009. Payment of the amounts owning under the terms of the notes is due upon the earlier to occur of (a) a change in control of the Company (as defined in the notes), (b) the executive’s death or (c) the executive’s disability as (defined in the notes or in the respective executive’s written employment agreement). In addition, in the case of the notes payable to our former executives, payment of the notes would be triggered by the Company’s failure to pay the executive’s base salary in accordance with the terms and conditions of the executive’s employment agreement because of disability. In February 2017, Mr. Marshall and Dr. Marshall resigned from their positions with us and their employment was terminated. At that time, we entered into the Ed Marshall Severance Agreement and a similar severance agreement with Dr. Marshall (collectively, the “Marshall Severance Agreements”). Under the terms of the Marshall Severance Agreements, we agreed to the modification of the promissory notes we previously issued to the Marshalls (collectively, the “Marshall Notes”) to require monthly principal payments to Mr. Marshall of $14,000 and to Dr. Marshall of $6,900 and to waive interest except in the event of a default. We made the first payments under the Marshall Notes, but have been in default under the Marshall Notes since April 2017, and as of December 31, 2017, we owed principal of owe principal payments for approximately nine months totaling $122,500 to Mr. Marshall and to Dr. Marshall totaling $58,600. In addition, under the terms of the Marshall Notes, as a result of our default, the Marshall Notes now accrue default until payment of the default amounts at the rate of 5% of the total amount of the notes. On March 1, 2017, the Company entered into an employment agreement with David Esposito to fill the position of Chairman and Interim CEO. The agreement stated the terms of his employment and compensation. Mr. Esposito’s compensation consisted of: (1) an annual base salary of $225,000; (2) a potential target bonus of up to 50% of base salary based on performance goals determined by the Board of Directors of the Company; (3) equity awards, and (4) standard employee benefits, including vacation. Mr. Esposito stepped down from his position as Interim CEO upon the appointment of David Dodd as the Company’s CEO effective September 18, 2017. As of September 30, 2017, the Company has accrued wages to Mr. Esposito of $123,750. Mr. Esposito remains as the Company’s Chairman of the Board of Directors. On September 15, 2017, the Company entered into an employment agreement with David Dodd as the Company’s CEO and a member of the Board of Directors of the Company. The agreement states the terms of his employment and compensation which consists of: (1) an annual base salary of $250,000; (2) an initial target bonus of up to 65% of annual base salary based on targets established by the Board of Directors; (3) a signing bonus of 1,000,000 shares of restricted stock; (4) an additional 1,000,000 shares of restricted stock that will vest upon successful commercialization of the AsepticSure ® On November 1, 2017, the Company entered into an employment agreement with Philip Theodore as the Company’s Executive Vice President, Operations and Administration. The agreement states the terms of his employment and compensation which consists of (1) an annual base salary of $175,000; (2) an initial target bonus of up to 45% of his annual base salary based on targets established by the Board of Directors; (3) a signing bonus of 300,000 shares of restricted stock upon his appointment; (4) an additional 300,000 shares of restricted stock that will vest upon successful commercialization of the AsepticSure ® In November 2017, the Company entered into change of control agreements with Michael Shannon, President of CFGH and Stephanie Sorensen, the Company’s Chief Financial Officer, with similar terms with the change of control agreements entered into with Mr. Dodd and Mr. Theodore. Supply and License Agreement On October 26, 2017, the Company entered into a supply and license agreement with Innovasource, LLC, (“Innovasource”) a leading manufacturer of cleaning, deodorizing and disinfecting products. Innovasource has agreed to supply the Company with its custom-formulated disinfectant product and has granted the Company an exclusive, non-transferable limited license to use its intellectual property in the marketing and sale of the AsepticSure ® Distribution and License Agreements In December 2016, the Company terminated a Distribution and License Agreement with a distributor due to lack of market development by the distributor. On October 25, 2017, the Company entered into an exclusive distribution agreement with Aglon a/s for the countries of Norway, Sweden, Finland, Denmark, and Iceland. Other Payables As of December 31, 2017, and 2016, the Company has recorded other payables totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over 10 years. The statute of limitations relating to these payables has passed. Although management of the Company does not believe that the amounts will be paid, the amounts have been recorded as other payables until such time as the Company is certain that no liability exists. Operating Leases The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is June 30, 2016 through June 29, 2018 with a monthly lease payment of $3,550 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). The future minimum lease payments due under this agreement are $21,300 CD plus the applicable goods and services tax. The Company has a month-to-month cancelable lease for office space located in Michigan, with monthly payments of approximately $1,000.

NOTE 11 - EQUITY TRANSACTIONS

NOTE 11 - EQUITY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 11 - EQUITY TRANSACTIONS Recapitalization On December 15, 2016, the Company’s stockholders approved the Board of Directors’ recommendation to increase the number of authorized shares of common stock from 395,000,000 to 500,000,000 shares in order to provide the Company with sufficient authorized shares to accomplish its objectives. The Company filed an amendment to modify its Articles of Incorporation with the State of Nevada on January 4, 2017, which was approved by the Secretary of State on January 24, 2017. The Company’s amended Articles of Incorporation include a class of preferred stock, par value $0.00001, with authorized shares of 50,000,000. To date, no shares of preferred stock have been issued. The rights and preferences of the authorized preferred shares will be determined by the Company’s Board of Directors. Common Stock Issuances During January 2016, the Company issued 500,000 restricted shares of common stock to a consultant. The fair value of the shares on the date of grant was $48,000, or $0.096 per share. The Company recorded compensation expense of $48,000 in connection with the issuance of the shares. During May 2017, the Company issued 250,000 restricted shares of common stock to a consultant. The fair value of the shares on the date of the grant was $17,500, or $0.07 per share. The Company recorded compensation expense of $17,500 in connection with the issuance of the shares. During the year ended December 31, 2017, the Company granted three of its executives and officers a total of 2,300,000 restricted shares of common stock upon their appointment to their positions. The aggregate value of the shares on their dates of grant was $228,000, with values ranging from $0.06 to $0.15 per share. The Company recorded compensation expense of $228,000 in connection with the issuance of the shares. During the year ended December 31, 2017, the Company issued and sold 11,833,334 restricted shares of common stock for net proceeds of $675,000 and an average price of $0.06 per share as part of a private offering to accredited investors, which included the Company’s Chairman and Interim CEO, its current CEO, Executive Vice President, Administration and Operations, Executive Vice President, Chief Commercial Officer and an independent director. Common Stock Options and Awards The Company recognizes stock-based compensation expense for grants of stock option awards, stock awards, restricted stock units and restricted stock under the Company’s Incentive Plan to employees and nonemployee members of the Company’s Board of Directors. In addition, the Company grants stock options to nonemployee consultants from time to time in consideration for services performed for the Company. The Company’s 2016 Equity Incentive Award Plan (the “2016 Plan”) was approved on December 15, 2016 by the stockholders to replace the Company’s 2008 Equity Incentive Plan, 2009 Incentive Stock Plan, 2012 Equity Incentive Award Plan, and the 2014 Equity Incentive Plan (collectively, the “Prior Plans”). Options and awards previously granted under the Prior Plans that have not yet expired by their terms will remain outstanding until their expiration dates. Following adoption of the 2016 Plan, the Company no longer made any grants or awards under the Prior Plans. The 2016 Plan reserves a total of 10,000,000 shares of common stock for awards. Awards under the 2016 Plan expire 10 years from the date of grant. Under the 2016 Plan, as of December 31, 2017, the Company had granted options, net of forfeitures, for the purchase of a total of 6,400,000 shares, had awarded 2,300,000 fully vested restricted shares, and an additional 1,300,000 shares to vest upon achievement of certain performance milestones. No shares are available for future grants or awards under the 2016 Plan. The Company estimates the fair value of each stock option award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including volatility of the Company’s stock price, the weighted average risk-free interest rate, and the expected life of the options. Because the Company does not pay dividends, the dividend rate variable used in the Black-Scholes option-pricing model is zero. Under the provisions of ASU 2016-09, the Company has elected to recognize forfeitures as they occur to determine the amount of compensation cost to be recognized in each period. For the year ended December 31, 2017 and 2016, the Company recorded stock-based compensation of $565,651 $ and $0, respectively, of which $89,064 related to the modification of vesting relating to 750,000 options issued in 2014 to Mr. Esposito. As of December 31, 2017, the Company had outstanding unvested options for a total of 325,000 shares with related unrecognized expense of approximately $19,760 and weighted average remaining life of 7.59 years. The Company will recognize this expense over the service period or when the achievement of the required milestones becomes probable. During 2017, the Company estimated the fair value of the stock options at the date of each grant based on the following weighted average assumptions: Risk-free interest rate 1.36% to 1.99 % Expected life 5 years Expected volatility 98.38% to 101.86 % Dividend yield 0.00 % The following is a summary of the status of the Company’s outstanding options as of December 31, 2017 and changes during the year then ended: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value As of December 31, 2016 20,715,000 $ 0.143 2.08 $ 261,220 Granted 6,900,000 0.097 Forfeited (7,550,000 ) 0.202 Surrendered (1,977,500 ) 0.128 As of December 31, 2017 18,087,500 0.102 3.72 - Exercisable 17,762,500 0.103 3.79 - No shares are expected to vest within the next 60 days. In December 2017, former and current directors, officers, employees and consultants voluntarily surrendered 1,977,500 shares in an effort to reduce the number of shares reserved resulting in an increase in shares available to be used for additional financing efforts. As of December 31, 2017, the aggregate intrinsic value of the outstanding vested options was $0. No shares were exercised in 2017. A summary of unvested stock option activity for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2016 1,075,000 $ 0.11 Awarded 1,000,000 0.08 Vested (250,000 ) 0.06 Forfeited (500,000 ) 0.10 Surrendered (1,000,000 ) 0.1095 Non-vested balance as of December 31, 2017 325,000 0.08 Warrants During October 2016, the Company issued warrants to purchase up to $1,000,000 in common stock with the number of shares determined based on a 20-day average stock price prior to the date of exercise with the exercise prices discounted 40%. The warrants were exercisable between January 31, 2017 and January 30, 2018. The warrants expired on January 30, 2018. During May 2017, the Company issued a warrant to purchase up to 750,000 shares of common stock at an exercise price of $0.10 per share to a third-party consultant. The warrant will vest when certain milestones are achieved and will expire three years from the date of issuance. During October 2017, the Company issued a warrant to purchase up to 1,000,000 shares of common stock at an exercise price of $0.10 per share to a supplier. The warrant immediately vested and will expire five years from the date of issuance. The Company recorded expense of $33,960 resulting from the issuance of this warrant.

NOTE 12 - GOING CONCERN

NOTE 12 - GOING CONCERN	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 12 - GOING CONCERN Continuation of the Company as a going concern is dependent upon obtaining additional capital and ultimately, upon the Company attaining profitable operations. The Company will require substantial additional funds to create a commercial organization to continue to develop its products, obtain FDA approval, product manufacturing, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will most likely be forced to substantially reduce or cease operations. The Company believes that it will need approximately $1,500,000 during the next 12 months for continued commercial operations, research and development, as well as for general corporate purposes. During 2017, the Company raised a total of $675,000 through the sale of 11,833,334 shares of common stock at an average price of $0.06 per share. On January 31, 2018, the Company raised net proceeds of $250,000 from the sale of identical unsecured convertible promissory notes and secured an equity credit line for up to $10,000,000 shares of common stock pursuant to certain terms of the agreement being met and sufficient shares outstanding available for sale (see Note 13). The ability of the Company to continue as a going concern is dependent on successfully accomplishing the plan described in the preceding paragraphs and eventually attaining profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 13 - SUBSEQUENT EVENTS

NOTE 13 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 13 - SUBSEQUENT EVENTS The Company evaluated subsequent events through the filing date of the Annual Report on Form 10-K and determined to disclose the following events. On January 30, 2018, the Company entered into an employment agreement with Jude Dinges as the Company’s Executive Vice President – Chief Commercial Officer. The agreement states the terms of his employment and compensation which consists of (1) an annual base salary of $175,000; (2) an initial target bonus of up to 45% of his annual base salary based on targets established by the Board of Directors; (3) a signing bonus of 300,000 restricted shares of common stock vesting upon successful commercialization of the AsepticSure ® Also, on January 31, 2018, the Company entered into an equity purchase agreement (the “Equity Purchase Agreement”) with the Investors, which was subsequently amended on March 16, 2018 (as amended, the “Purchase Agreement”), pursuant to which the investors committed to purchase in the aggregate up to $10,000,000 of value of common stock. In consideration of their commitment under the Purchase Agreement, on January 31, 2018, the Company issued to each Investor 4,087,193 shares of common stock (the “Commitment Shares”) as a commitment fee. The Company’s right to issue and sell shares of common stock under the Equity Purchase Agreement to the investors is subject to the satisfaction of certain conditions, including, but not limited to, an effective registration statement for resale of such shares by the investors. On February 12, 2018, the Company filed a Registration Statement with the Securities and Exchange Commission on Form S-1 to register 22,233,427 shares of common stock that may be issued under the Equity Purchase Agreement for resale by the investors. The Securities and Exchange Commission is reviewing the Registration Statement. Between January 1 and March 13, 2018, the Company’s former and current directors, executives, employees and consultants voluntarily surrendered restricted stock awards for a total of 1,300,000 shares of common stock and stock option grants for the purchase of a total of 7,280,000 shares to increase the number of shares available for financing transactions under the Equity Purchase Agreement.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Organization The consolidated financial statements presented are those of Medizone International, Inc. (“Medizone”), Medizone Canada, Inc., a wholly owned subsidiary, and the Canadian Foundation for Global Health (“CFGH”) (“Affiliate”), a not-for-profit foundation based in Ottawa, Canada, considered to be a variable interest entity (“VIE”) as described below. Collectively, they are referred to herein as the “Company.” In late 2008, the Company assisted in the formation of CFGH, a not-for-profit foundation. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of its technology to as many in need as possible. US generally accepted accounting principles (“US GAAP”) require a VIE to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests (ownership, contractual, or other financial interests) in the VIE. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the financial results of the VIE with it. Accordingly, the financial position and results of operations of CFGH are consolidated with Medizone as of and for the years ended December 31, 2017 and 2016. The noncontrolling interest portion of net assets and net loss not attributable, directly or indirectly, to Medizone International, Inc. is considered immaterial. b. The Company is a global provider of disinfection systems. The Company invented the AsepticSure ® ®
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss Per Common Share The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the years as follows: For the Years Ended 2017 2016 Numerator (net loss) $ (2,013,799 ) $ (2,673,836 ) Denominator (weighted average number of common shares outstanding – basic and diluted) 400,207,813 375,118,494 Basic and diluted net loss per common share $ (0.01 ) $ (0.01 ) As of December 31, 2017, common stock equivalents, consisting of 18,087,500 options, warrants to purchase 1,750,000 shares of common stock, and warrants to purchase up to $1,000,000 of common stock with the number of shares determined based on a 20-day average stock price prior to the date of exercise, have not been included in the calculation, as their effect is antidilutive for the year ended December 31, 2017. As of December 31, 2016, common stock equivalents, consisting of 20,715,000 options and warrants to purchase up to $1,000,000 of common stock with the number of shares to be determined based on similar terms as in 2017, have not been included in the calculation, as the effect is antidilutive for the year ended December 31, 2016.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost. Any major additions and improvements are capitalized. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as gain or loss on sale of property and equipment. Depreciation is computed using the straight-line method over periods of three years for computers and software, and five years for office equipment and furniture.
Income Tax, Policy [Policy Text Block]	Provision for Income Taxes The Company estimates income taxes in each of the jurisdictions in which it operates. This process involves estimating the Company’s actual current income tax expense together with assessing temporary differences resulting from differing treatment of items for income tax and financial reporting purposes. These temporary differences result in deferred income tax assets and liabilities, the net amount of which is included in the Company’s consolidated balance sheets. When appropriate, the Company records a valuation allowance to reduce its deferred income tax assets to the amount that the Company believes is more likely than not to be realized. Key assumptions used in estimating a valuation allowance include potential future taxable income, projected income tax rates, expiration dates of net operating loss (“NOL”) and tax credit carry forwards, and ongoing prudent and feasible tax planning strategies. As of December 31, 2017, the Company had NOL carryforwards of approximately $14,087,000 that may be offset against future taxable income, if any, and expire through 2035. If substantial changes in the Company’s ownership should occur, there would also be an annual limitation of the amount of the NOL carryforwards available for use. No tax benefit has been reported in the consolidated financial statements as, in the opinion of management, it is more likely than not that all of the deferred income tax assets will not be realized and the NOL carryforwards will expire unused. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. If the Company were to determine that it would be able to realize its deferred income tax assets in the future in excess of the net recorded amount, an adjustment to reduce the valuation allowance would increase net income or decrease net loss in the period such determination was made. Interest and penalties associated with any underpayment of income taxes would be classified as income tax provision in the statements of comprehensive loss. The Company has elected to present revenues net of any tax collected. Deferred income tax assets as of December 31, 2017 and 2016 comprised the following: 2017 2016 Net operating loss carryforwards $ 3,514,700 $ 4,959,900 Related party accruals 980,100 1,564,700 Valuation allowance (4,494,800 ) (6,524,600 ) $ - $ - The income tax benefit differs from the amount determined by applying the U.S. federal income tax rate to pretax loss for the years ended December 31, 2017 and 2016 due to the following: 2017 2016 Income tax benefit based on U.S. statutory rate of 34% $ (684,700 ) $ (909,100 ) Effect of change in deferred tax rates (39.834% to 24.95%) 2,681,404 - Other 33,096 (40,800 ) Change in valuation allowance (2,029,800 ) 949,900 $ - $ - The Company had no uncertain income tax positions as of December 31, 2017, and 2016. The Company files income tax returns in the U.S. federal, California and Michigan jurisdictions. With few exceptions, the Company is no longer subject to US federal, state and local tax examinations for years before 2014. On December 22, 2017, the Tax Cuts and Jobs Act (the Tax Act) was enacted. The Tax Act makes broad and complex changes to the US tax code that will affect our fiscal year ending December 31 2018, including, but not limited to (1) reducing the US federal corporate tax rate from 35 percent to 21 percent; (2) generally eliminating U.S. federal income taxes on dividends from foreign subsidiaries; (3) requiring a current inclusion in US federal taxable income of certain earnings of controlled foreign corporations; (4) creating a new limitation on deductible interest expense; (5) revising the rules that limit the deductibility of compensation to certain highly compensated executives, and (6) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. The SEC staff issued SAB 118, which provides guidance on accounting for the tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the Tax Act. As a result of changes made by the Tax Act, Section 162(m) will limit the deduction of compensation, including performance-based compensation, in excess of $1 million paid to anyone who, for tax years beginning after January 1, 2018, serves as the Chief Executive Officer or Chief Financial Officer, or who is among the three most highly compensated executive officers for any fiscal year. The only exception to this rule is for compensation that is paid pursuant to a binding written contract in effect on November 2, 2017 that would have otherwise been deductible under the prior Section 162(m) rules. Accordingly, any compensation paid in the future pursuant to new compensation arrangements entered into after November 2, 2017, even if performance-based, will count towards the $1 million fiscal year deduction limit if paid to a covered executive. The Company estimates that there will not be a material impact during the current quarter or fiscal year, as the law is effective for tax years beginning after January 1, 2018. The Company has evaluated its binding contracts entered into prior to November 2, 2017 and believes there will be no material impact on the Company’s balance sheet. The Company is still analyzing certain aspects of the Act and refining calculations, which could potentially affect the impact of the Company’s deferred tax asset and this provision.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of Medizone and the accounts of Medizone Canada, Inc., a wholly-owned subsidiary incorporated in Canada, and CFGH, a VIE. All material intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of the contingent assets and liabilities as of the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Advertising Costs, Policy [Policy Text Block]	Advertising The Company expenses the costs of advertising as incurred. The Company did not incur any advertising expense for the years ended December 31, 2017 and 2016.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Options The Company records compensation expense in connection with the granting of stock options and their vesting periods based on their fair values. The Company estimates the fair values of stock option awards issued to employees, consultants and others by using the Black-Scholes option-pricing model. For stock options with a service condition, the expense is measured at the grant date and expensed over the vesting period. For stock options with a performance condition, the expense is measured when it is probable that the performance condition will be met, subsequently re-measured at each reporting date, and trued up upon the final completion of the performance condition.
Derivatives, Policy [Policy Text Block]	Common Stock Warrant Liability The Company accounts for certain common stock warrants as liabilities. The fair value of the common stock warrant liability is determined at each reporting period-end, with the changes in fair value recognized as gain (loss) on change in fair value of warrant liability. The fair value of the warrants to purchase common stock is estimated using the Black-Scholes valuation model. The significant assumptions used in estimating the fair value of warrant liabilities include the exercise price, volatility of the stock underlying the warrant, risk-free interest rate, estimated fair value of the stock underlying the warrant and the estimated life of the warrant.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Trademark and Patents Trademark and patents are recorded at cost. Amortization is computed using the straight-line method over a period of seven years. The Company evaluates the recoverability of intangibles and reviews the amortization period on a continual basis. Several factors are used to evaluate intangibles, including management’s plans for future operations, recent operating results, and projected, undiscounted net cash flows.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Policy The Company recognizes revenue when it ships its products, title and risk of loss passes to customers, payment from the customer is reasonably assured and the price is fixed or determinable. The Company records customer deposits received in advance of shipping products as a liability.
Inventory, Policy [Policy Text Block]	Inventory The Company’s inventory consists of its AsepticSure ®
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company’s financial instruments consist of cash, accounts payable, accrued expenses, notes payable and warrant liability. The carrying amounts of cash, accounts payable, and accrued expenses approximate their fair values because of the short-term nature of these instruments. The carrying amounts of the notes payable approximate fair values as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments. The fair value of the warrant liability represents its estimated fair value using the Black-Scholes option pricing model. The Company measures certain financial liabilities (warrant liability) at fair value on a recurring basis. The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest priority to measurements involving significant unobservable inputs (Level 3). The three levels of the fair value hierarchy are as follows: · Level 1 measurements are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. · Level 2 measurements are inputs other than quoted prices included in Level 1 that are observable either directly or indirectly. ·
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) In February 2016, the FASB released ASU No. 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting In October 2016, the FASB issued ASU No. 2016-17, Interests held Through Related Parties That are Under Common Control In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718)
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk The Company maintains its cash in bank deposit accounts which cash, at times, exceeds federally insured limits. As of December 31, 2017, the Company did not have cash balances that exceeded US federally insured limits. To date, the Company has not experienced a material loss or lack of access to its cash; however, no assurance can be provided that access to the Company’s cash will not be impacted by adverse conditions in the financial markets.

NOTE 1 - ORGANIZATION AND SUM22

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the years as follows: For the Years Ended 2017 2016 Numerator (net loss) $ (2,013,799 ) $ (2,673,836 ) Denominator (weighted average number of common shares outstanding – basic and diluted) 400,207,813 375,118,494 Basic and diluted net loss per common share $ (0.01 ) $ (0.01 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred income tax assets as of December 31, 2017 and 2016 comprised the following: 2017 2016 Net operating loss carryforwards $ 3,514,700 $ 4,959,900 Related party accruals 980,100 1,564,700 Valuation allowance (4,494,800 ) (6,524,600 ) $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The income tax benefit differs from the amount determined by applying the U.S. federal income tax rate to pretax loss for the years ended December 31, 2017 and 2016 due to the following: 2017 2016 Income tax benefit based on U.S. statutory rate of 34% $ (684,700 ) $ (909,100 ) Effect of change in deferred tax rates (39.834% to 24.95%) 2,681,404 - Other 33,096 (40,800 ) Change in valuation allowance (2,029,800 ) 949,900 $ - $ -

NOTE 3 - TRADEMARK AND PATENTS

NOTE 3 - TRADEMARK AND PATENTS (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents consist of the following as of December 31, 2017 and 2016: 2017 2016 Patent costs $ 433,865 $ 415,251 Trademark 770 770 434,635 416,021 Accumulated amortization (317,019 ) (264,577 ) Trademark and patents, net $ 117,616 $ 151,444

NOTE 5 - ACCRUED EXPENSES (Tabl

NOTE 5 - ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2017
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Current Liabilities [Table Text Block]	Accrued expenses consist of the following as of December 31, 2017 and 2016: 2017 2016 Accrued interest $ 577,978 $ 549,909 Other accruals 52,921 42,712 Total $ 630,899 $ 592,621

NOTE 6 - ACCRUED EXPENSES - R25

NOTE 6 - ACCRUED EXPENSES - RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses – related parties consist of the following as of December 31, 2017 and 2016: 2017 2016 Accrued payroll and consulting – related parties $ 648,167 $ 422,334 Accrued payroll taxes – related parties 131,877 116,553 Total $ 780,044 $ 538,887

NOTE 7 - NOTES PAYABLE (Tables)

NOTE 7 - NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable consist of the following as of December 31, 2017 and 2016: 2017 2016 Unsecured notes payable to former directors and a family member of a former director, due at various dates in 1995, 1996 and 1997, interest at 8%. The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. These notes payable are in default. $ 182,676 $ 182,676 Unsecured notes payable to a third party in the amount of $50,000, due on September 8, 2018, interest at 12%. Accrued interest due semi-annually, January 5 and July 5 of each year. The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share. 50,000 50,000 Unsecured notes payable to 10 stockholders, due on demand, interest at 10%. The Company is obligated to accept the principal at face value plus accrued interest as partial payment for shares the lenders may purchase from the Company upon exercise of the lenders’ option to acquire shares from the Company. 60,815 60,815 Unsecured notes payable to a third party in the amount of $25,000, due on September 17, 2018, interest at 12%. Accrued interest due semi-annually, January 5 and July 5 of each year. The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share. 25,000 25,000 Unsecured notes payable to directors totaling $28,000 and a note payable to a third party in the amount of $9,000, due on April 22, 1995, interest at 8%. Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. These notes payable are in default. 37,000 37,000 Unsecured notes payable to a financing company, payable in nine monthly installments, interest ranging from 5.1% to 7.3%, maturing in April, July and October 2018. 6,732 16,841 Total notes payable 362,223 372,332 Less notes payable current portion (362,223 ) (297,332 ) Total notes payable long term, net of current portion $ - $ 75,000

NOTE 9 - WARRANT LIABILITY (Tab

NOTE 9 - WARRANT LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The estimate was calculated using the following inputs: Input December 31, 2017 December 31, 2016 Risk-free interest rate 1.28 % .85 % Expected life in years 1 month 1 year Dividend yield — — Volatility 136.3 % 120.0 % Stock price $ 0.04 $ 0.11

NOTE 11 - EQUITY TRANSACTIONS (

NOTE 11 - EQUITY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	During 2017, the Company estimated the fair value of the stock options at the date of each grant based on the following weighted average assumptions: Risk-free interest rate 1.36% to 1.99 % Expected life 5 years Expected volatility 98.38% to 101.86 % Dividend yield 0.00 %
Schedule of Stock Options Roll Forward [Table Text Block]	The following is a summary of the status of the Company’s outstanding options as of December 31, 2017 and changes during the year then ended: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value As of December 31, 2016 20,715,000 $ 0.143 2.08 $ 261,220 Granted 6,900,000 0.097 Forfeited (7,550,000 ) 0.202 Surrendered (1,977,500 ) 0.128 As of December 31, 2017 18,087,500 0.102 3.72 - Exercisable 17,762,500 0.103 3.79 -
Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of unvested stock option activity for the year ended December 31, 2017 is presented below: Number of Shares Weighted Average Grant Date Fair Value Non-vested balance as of December 31, 2016 1,075,000 $ 0.11 Awarded 1,000,000 0.08 Vested (250,000 ) 0.06 Forfeited (500,000 ) 0.10 Surrendered (1,000,000 ) 0.1095 Non-vested balance as of December 31, 2017 325,000 0.08

NOTE 1 - ORGANIZATION AND SUM29

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Dec. 22, 2017	Dec. 21, 2017	Oct. 21, 2016	Dec. 31, 2017	Dec. 31, 2016
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Common Stock Equivalents, Value			$ 1,000,000	$ 1,000,000	$ 1,000,000
Operating Loss Carryforwards				$ 14,087,000
Operating Loss Carryforwards, Expiration Date				2,035
Liability for Uncertainty in Income Taxes, Current				$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%		34.00%	34.00%
Employee Stock Option [Member]
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)				18,087,500	20,715,000
Warrant [Member]
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)				1,750,000
Trademarks [Member]
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life				7 years
Computer Equipment [Member]
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life				3 years
Office Equipment [Member]
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life				5 years

NOTE 1 - ORGANIZATION AND SUM30

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Earnings Per Share, Basic and Diluted [Abstract]
Numerator (net loss)	$ (2,013,799)	$ (2,673,836)
Denominator (weighted average number of common shares outstanding – basic and diluted)	400,207,813	375,118,494
Basic and diluted net loss per common share	$ (0.01)	$ (0.01)

NOTE 1 - ORGANIZATION AND SUM31

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carryforwards	$ 3,514,700	$ 4,959,900
Related party accruals	980,100	1,564,700
Valuation allowance	(4,494,800)	(6,524,600)
	$ 0	$ 0

NOTE 1 - ORGANIZATION AND SUM32

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Income tax benefit based on U.S. statutory rate of 34%	$ (684,700)	$ (909,100)
Effect of change in deferred tax rates (39.834% to 24.95%)	2,681,404	0
Other	33,096	(40,800)
Change in valuation allowance	(2,029,800)	949,900
	$ 0	$ 0

NOTE 1 - ORGANIZATION AND SUM33

NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Effective Income Tax Rate Reconciliation (Parentheticals)	Dec. 22, 2017	Dec. 21, 2017	Dec. 31, 2017	Dec. 31, 2016
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Income tax benefit statutory rate	21.00%	35.00%	34.00%	34.00%

NOTE 2 INVENTORY (Details)

NOTE 2 INVENTORY (Details)	1 Months Ended
	Dec. 31, 2016USD ($)
Inventory Disclosure [Abstract]
Number of Units Returned	5
Unit, Discount Rate	$ 25,000

NOTE 3 - TRADEMARK AND PATENT35

NOTE 3 - TRADEMARK AND PATENTS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure Text Block [Abstract]
Amortization of Intangible Assets	$ 52,442	$ 55,896
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	41,409
Finite-Lived Intangible Assets, Amortization Expense, Year Two	27,745
Finite-Lived Intangible Assets, Amortization Expense, Year Three	20,203
Finite-Lived Intangible Assets, Amortization Expense, Year Four	12,956
Finite-Lived Intangible Assets, Amortization Expense, Year Five	8,412
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	$ 6,891

NOTE 3 - TRADEMARK AND PATENT36

NOTE 3 - TRADEMARK AND PATENTS (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 434,635	$ 416,021
Accumulated amortization	(317,019)	(264,577)
Trademark and patents, net	117,616	151,444
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	433,865	415,251
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 770	$ 770

NOTE 4 - ACCOUNTS PAYABLE - R37

NOTE 4 - ACCOUNTS PAYABLE - RELATED PARTIES (Details) - USD ($)	1 Months Ended
	Jul. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
NOTE 4 - ACCOUNTS PAYABLE - RELATED PARTIES (Details) [Line Items]
Accounts Payable, Related Parties, Current		$ 40,415	$ 0
Accounts Payable [Member]
NOTE 4 - ACCOUNTS PAYABLE - RELATED PARTIES (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 228,109

NOTE 5 - ACCRUED EXPENSES (Deta

NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Accrued Liabilities [Abstract]
Accrued interest	$ 577,978	$ 549,909
Other accruals	52,921	42,712
Total	$ 630,899	$ 592,621

NOTE 6 - ACCRUED EXPENSES - R39

NOTE 6 - ACCRUED EXPENSES - RELATED PARTIES (Details)	1 Months Ended
	Jul. 31, 2016USD ($)
Accounts Payable and Accrued Liabilities [Member]
NOTE 6 - ACCRUED EXPENSES - RELATED PARTIES (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 1,389,772

NOTE 6 - ACCRUED EXPENSES - R40

NOTE 6 - ACCRUED EXPENSES - RELATED PARTIES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Schedule of Accrued Liabilities [Abstract]
Accrued payroll and consulting – related parties	$ 648,167	$ 422,334
Accrued payroll taxes – related parties	131,877	116,553
Total	$ 780,044	$ 538,887

NOTE 7 - NOTES PAYABLE (Detail

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt - USD ($)	Dec. 31, 2017	Dec. 31, 2016
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	$ 362,223	$ 372,332
Less notes payable current portion	(362,223)	(297,332)
Note Payable	0	75,000
Loans Payable [Member] | Unsecured Note 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	182,676	182,676
Loans Payable [Member] | Unsecured Note 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	50,000	50,000
Loans Payable [Member] | Unsecured Note 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	60,815	60,815
Loans Payable [Member] | Unsecured Note 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	25,000	25,000
Loans Payable [Member] | Unsecured Note 5 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	37,000	37,000
Loans Payable [Member] | Unsecured Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Note Payable	$ 6,732	$ 16,841

NOTE 7 - NOTES PAYABLE (Deta42

NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals)	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares	Dec. 31, 2016USD ($)$ / shares	Jul. 31, 2016USD ($)
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	5.00%
Notes Payable, Amount			$ 1,617,881
Loans Payable [Member] | Unsecured Note 1 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Due	Various dates in 1995, 1996 and 1997	Various dates in 1995, 1996 and 1997
Interest	8.00%	8.00%
Due	The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur.	The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur.
Loans Payable [Member] | Unsecured Note 2 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	12.00%	12.00%
Due	Accrued interest due semi-annually, January 5 and July 5 of each year.	Accrued interest due semi-annually, January 5 and July 5 of each year.
Due	Sep. 8, 2018	Sep. 8, 2018
Right to Convert	The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share.	The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share.
Right to Convert, per share | $ / shares	$ 0.10	$ 0.10
Notes Payable, Amount	$ 50,000
Loans Payable [Member] | Unsecured Note 3 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	10.00%	10.00%
Stockholders	10	10
Loans Payable [Member] | Unsecured Note 4 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	12.00%	12.00%
Due	Accrued interest due semi-annually, January 5 and July 5 of each year.	Accrued interest due semi-annually, January 5 and July 5 of each year.
Due	Sep. 17, 2018	Sep. 17, 2018
Right to Convert	The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share.	The note holder has the right to convert 20% of the then outstanding principal into common shares at $0.10 per share.
Right to Convert, per share | $ / shares	$ 0.10	$ 0.10
Notes Payable, Amount	$ 25,000
Loans Payable [Member] | Unsecured Note 5 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	8.00%	8.00%
Due	Apr. 22, 1995	Apr. 22, 1995
Right to Convert	Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction.	Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction.
Note Default	These notes payable are in default.	These notes payable are in default.
Loans Payable [Member] | Unsecured Note 5 [Member] | Third Party Debt [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Notes Payable, Amount	$ 9,000	$ 9,000
Loans Payable [Member] | Unsecured Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Due	April, July and October 2018	April, July and October 2018
Due	Nine monthly installments	Nine monthly installments
Loans Payable [Member] | Minimum [Member] | Unsecured Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	5.10%	5.10%
Loans Payable [Member] | Maximum [Member] | Unsecured Note 6 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Interest	7.30%	7.30%
Loans Payable [Member] | Director [Member] | Unsecured Note 5 [Member]
NOTE 7 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items]
Notes Payable, Amount	$ 28,000	$ 28,000

NOTE 8 - NOTES PAYABLE - RELA43

NOTE 8 - NOTES PAYABLE - RELATED PARTIES (Details)	1 Months Ended	12 Months Ended
	Jul. 31, 2016USD ($)	Dec. 31, 2017USD ($)
NOTE 8 - NOTES PAYABLE - RELATED PARTIES (Details) [Line Items]
Number of Notes	3
Debt Instrument, Face Amount	$ 1,617,881
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Officer [Member]
NOTE 8 - NOTES PAYABLE - RELATED PARTIES (Details) [Line Items]
Number of Notes	3
Debt Instrument, Face Amount	$ 1,617,881
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Repayments of Debt		$ 23,202
Interest Payable		$ 48,899
Accounts Payable [Member]
NOTE 8 - NOTES PAYABLE - RELATED PARTIES (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 228,109
Accounts Payable and Accrued Liabilities [Member]
NOTE 8 - NOTES PAYABLE - RELATED PARTIES (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 1,389,772

NOTE 9 - WARRANT LIABILITY (Det

NOTE 9 - WARRANT LIABILITY (Details) - USD ($)	Oct. 21, 2016	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Disclosure Text Block [Abstract]
Warrant, Description	In October 2016, the Company issued warrants to purchase up to $1,000,000 in common stock with the number of shares to be determined based on a 20-day average stock price prior to the date of exercise, discounted 40%.	number of shares determined based on a 20-day average stock price prior to the date of exercise with the exercise prices discounted 40%
Common Stock Equivalents, Value	$ 1,000,000		$ 1,000,000	$ 1,000,000
Derivative Liability, Current	$ 937,951		690,508	985,163
Derivative, Gain (Loss) on Derivative, Net			$ 294,655	$ (47,212)

NOTE 9 - WARRANT LIABILITY (De

NOTE 9 - WARRANT LIABILITY (Details) - Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Abstract]
Risk-free interest rate	1.28%	0.85%
Expected life in years	1 year	1 year
Dividend yield	0.00%	0.00%
Volatility	136.30%	120.00%
Stock price (in Dollars per share)	$ 0.04	$ 0.11

NOTE 10 - COMMITMENTS AND CON46

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details)

Jan. 04, 2018shares

Jan. 03, 2018shares

Nov. 01, 2017USD ($)shares

Sep. 15, 2017USD ($)shares

Mar. 01, 2017USD ($)

Dec. 31, 2017USD ($)shares

Dec. 31, 2016USD ($)

Jul. 31, 2016USD ($)

Dec. 31, 2017USD ($)shares

Dec. 31, 2017CAD ($)shares

Dec. 31, 2002USD ($)

Dec. 31, 2001USD ($)

Jul. 31, 2017USD ($)

Jan. 31, 2018USD ($)

Dec. 31, 2017CAD ($)

Sep. 30, 2017USD ($)

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Accounts Payable, Current

$ 637,557

$ 459,654

$ 637,557

Number of Notes

3

Debt Instrument, Face Amount

$ 1,617,881

Due to Related Parties

$ 58,600

$ 58,600

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

5.00%

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares

2,300,000

2,300,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (in Shares) | shares

1,977,500

Other Commitments, Description

the Company terminated a Distribution and License Agreement with a distributor due to lack of market development by the distributor.

Accounts Payable, Other, Current

$ 224,852

$ 224,852

$ 224,852

Minimum [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Notes Payable, Related Parties

122,500

122,500

Default Judgement [Member] | Rakas Litigation [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Accounts Payable, Current

$ 143,000

143,000

Operating Leases, Future Minimum Payments Due (in Dollars)

$ 21,300

Litigation Fees [Member] | Rakas Litigation [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Accounts Payable, Current

$ 21,308

Certified Laboratory Space [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 3,550

Subsequent Event [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Face Amount

$ 305,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Promissory Note 1 [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Face Amount

1,065,189

Promissory Note 2 [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Face Amount

444,583

Promissory Note 3 [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Face Amount

111,109

Accounts Payable- Related Party [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Conversion, Converted Instrument, Amount

228,109

Accrued Expenses - Related Parties [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Conversion, Converted Instrument, Amount

$ 1,389,772

Settlement Amount, September 2001 [Member] | Rakas Litigation [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Litigation Settlement, Amount Awarded to Other Party

$ 25,000

Settlement Amount, January 2002 [Member] | Default Judgement [Member] | Rakas Litigation [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Loss Contingency, Damages Sought, Value

$ 143,000

Building [Member] | Kalamazoo, Michigan [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Operating Leases, Rent Expense, Minimum Rentals

$ 1,000

Former CEO [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Periodic Payment

$ 14,000

Former Director of Operations [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Debt Instrument, Periodic Payment

$ 6,900

Chief Executive Officer [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Employment Agreement, Base Salary

$ 250,000

$ 225,000

Employment Agreement, Bonus Terms

an initial target bonus of up to 65% of annual base salary based on targets established by the Board of Directors

a potential target bonus of up to 50% of base salary based on performance goals determined by the Board of Directors of the Company

Employee-related Liabilities, Current

$ 123,750

Chief Executive Officer [Member] | Subsequent Event [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (in Shares) | shares

1,000,000

Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares

1,000,000

Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares

1,000,000

Executive Vice President [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Employment Agreement, Base Salary

$ 175,000

Employment Agreement, Bonus Terms

an initial target bonus of up to 45% of his annual base salary based on targets established by the Board of Directors

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period (in Shares) | shares

300,000

Executive Vice President [Member] | Share-based Compensation Award, Tranche One [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares

300,000

Executive Vice President [Member] | Share-based Compensation Award, Tranche Two [Member]

NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | shares

300,000

NOTE 11 - EQUITY TRANSACTIONS47

NOTE 11 - EQUITY TRANSACTIONS (Details) - USD ($)	Oct. 21, 2016	Dec. 31, 2017	Oct. 31, 2017	May 31, 2017	Oct. 31, 2016	Jan. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 15, 2016	Dec. 14, 2016
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Common Stock, Shares Authorized		408,317,402					408,317,402	393,934,068	500,000,000	395,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)		$ 0.00001					$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized		50,000,000					50,000,000	50,000,000
Stock Issued During Period, Shares, Issued for Services				250,000		500,000
Stock Issued During Period, Value, Issued for Services (in Dollars)				$ 17,500		$ 48,000	$ 17,500	$ 48,000
Shares Issued, Price Per Share (in Dollars per share)				$ 0.07		$ 0.096
Number of Officers							3
Stock Issued During Period, Shares, Restricted Stock Award, Gross							2,300,000
Stock Issued During Period, Value, Restricted Stock Award, Gross (in Dollars)							$ 228,000
Stock Issued During Period, Shares, New Issues							11,833,334
Proceeds from Issuance or Sale of Equity (in Dollars)							$ 675,000
Sale of Stock, Price Per Share (in Dollars per share)		$ 0.06					$ 0.06
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							6,400,000
Fair Value Assumptions, Expected Dividend Rate							0.00%	0.00%
Allocated Share-based Compensation Expense (in Dollars)							$ 228,000	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		325,000					325,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)		$ 19,760					$ 19,760
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition							7 years 215 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period		1,977,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)		$ 0					$ 0	261,220
Warrants, Maximum Value (in Dollars)					$ 1,000,000
Warrant, Description	In October 2016, the Company issued warrants to purchase up to $1,000,000 in common stock with the number of shares to be determined based on a 20-day average stock price prior to the date of exercise, discounted 40%.				number of shares determined based on a 20-day average stock price prior to the date of exercise with the exercise prices discounted 40%
Class of Warrant or Rights, Granted			1,000,000	750,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.10	$ 0.10
Warrant, Term			5 years	3 years
Issuance of Stock and Warrants for Services or Claims (in Dollars)							$ 33,960	937,951
Minimum [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)		$ 0.06					$ 0.06
Maximum [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)		$ 0.15					$ 0.15
Common Stock Awards, Vested [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							2,300,000
Common Stock Awards, Non-Vested [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							1,300,000
Employee Stock Option [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)							$ 565,651	$ 0
Options Modified [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars)							$ 89,064
Options Modified							750,000

NOTE 11 - EQUITY TRANSACTIONS

NOTE 11 - EQUITY TRANSACTIONS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	12 Months Ended
	Dec. 31, 2017
NOTE 11 - EQUITY TRANSACTIONS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Expected life	5 years
Dividend yield	0.00%
Minimum [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.36%
Expected volatility	98.38%
Maximum [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Risk-free interest rate	1.99%
Expected volatility	101.86%

NOTE 11 - EQUITY TRANSACTIONS49

NOTE 11 - EQUITY TRANSACTIONS (Details) - Schedule of Stock Options Roll Forward - USD ($)	Dec. 31, 2016	Dec. 31, 2017
Schedule of Stock Options Roll Forward [Abstract]
Balance, Number of Shares	20,715,000	18,087,500
Balance, Weighted Average Exercise Price	$ 0.143	$ 0.102
Balance, Weighted Average Remaining Contractual Term	2 years 29 days	3 years 262 days
Balance, Aggregate Intrinsic Value	$ 261,220	$ 0
Exercisable, Number of Shares		17,762,500
Exercisable, Weighted Average Exercise Price		$ 0.103
Exercisable, Weighted Average Remaining Contractual Term		3 years 288 days
Exercisable, Aggregate Intrinsic Value		$ 0
Granted, Number of Shares		6,900,000
Granted, Weighted Average Exercise Price		$ 0.097
Forfeited, Number of Shares		(7,550,000)
Forfeited, Weighted Average Exercise Price		$ 0.202
Surrendered, Number of Shares		(1,977,500)
Surrendered, Weighted Average Exercise Price		$ 0.128

NOTE 11 - EQUITY TRANSACTIONS50

NOTE 11 - EQUITY TRANSACTIONS (Details) - Share-based Compensation, Stock Options, Activity	12 Months Ended
	Dec. 31, 2017$ / sharesshares
NOTE 11 - EQUITY TRANSACTIONS (Details) - Share-based Compensation, Stock Options, Activity [Line Items]
Awarded, number of shares	6,900,000
Non-vested balance, number of shares	325,000
Non-Vested Options [Member]
NOTE 11 - EQUITY TRANSACTIONS (Details) - Share-based Compensation, Stock Options, Activity [Line Items]
Non-vested balance, number of shares	1,075,000
Non-vested balance, weighted average grant date fair value | $ / shares	$ 0.11
Awarded, number of shares	1,000,000
Awarded, weighted average grant date fair value | $ / shares	$ 0.08
Vested, number of shares	(250,000)
Vested, weighted average grant date fair value | $ / shares	$ 0.06
Forfeited, number of shares	(500,000)
Forfeited, weighted average grant date fair value | $ / shares	$ 0.10
Surrendered, number of shares	(1,000,000)
Surrendered, weighted average grant date fair value | $ / shares	$ 0.1095
Non-vested balance, number of shares	325,000
Non-vested balance, weighted average grant date fair value | $ / shares	$ 0.08

NOTE 12 - GOING CONCERN (Detail

NOTE 12 - GOING CONCERN (Details) - USD ($)	Jan. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
NOTE 12 - GOING CONCERN (Details) [Line Items]
Retained Earnings (Accumulated Deficit)		$ (40,085,981)	$ (38,072,182)
Working capital (deficit)		(4,667,093)
Stockholders' Equity Attributable to Parent		$ (4,546,654)	$ (4,046,145)	$ (2,569,234)
Substantial Doubt about Going Concern, Conditions or Events		The Company believes that it will need approximately $1,500,000 during the next 12 months for continued commercial operations, research and development, as well as for general corporate purposes.
Proceeds from Issuance or Sale of Equity		$ 675,000
Stock Issued During Period, Shares, New Issues (in Shares)		11,833,334
Sale of Stock, Price Per Share (in Dollars per share)		$ 0.06
Subsequent Event [Member]
NOTE 12 - GOING CONCERN (Details) [Line Items]
Proceeds from Convertible Debt	$ 250,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 10,000,000

NOTE 13 - SUBSEQUENT EVENTS (De

NOTE 13 - SUBSEQUENT EVENTS (Details) - USD ($)	Jan. 31, 2018	Jan. 30, 2018	Mar. 13, 2018	Dec. 31, 2017	Jul. 31, 2016
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)				2,300,000
Debt Instrument, Face Amount					$ 1,617,881
Debt Instrument, Interest Rate, Stated Percentage				5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares)				7,550,000
Subsequent Event [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Proceeds from Convertible Debt	$ 250,000
Debt Instrument, Face Amount	$ 305,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Debt Instrument, Term	6 months
Debt Instrument, Unamortized Discount	$ 35,000
Debt Issuance Costs, Gross	$ 20,000
Debt Default Interest Rate	24.00%
Debt Penalty, Percentage	40.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.05
Equity Purchase Agreement, Maximum Value	$ 10,000,000
Stock Issued During Period, Shares, Other (in Shares)	4,087,193
Common Stock, Capital Shares Reserved for Future Issuance (in Shares)	22,233,427
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares)			1,300,000
Equity Purchase Agreement, Number of Additional Shares Available (in Shares)			7,280,000
Subsequent Event [Member] | Proceeds From Each Note [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Proceeds from Convertible Debt	$ 125,000
Subsequent Event [Member] | Chief Commercial Officer [Member]
NOTE 13 - SUBSEQUENT EVENTS (Details) [Line Items]
Employment Agreement, Base Salary		$ 175,000
Employment Agreement, Bonus Terms		an initial target bonus of up to 45% of his annual base salary based on targets established by the Board of Directors
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)		300,000